Tamara van Donge

Chapter 11 240 19. Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. The Journal of Clinical Pharmacology. 2013;53(3):305-313. 20. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560. 21. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatric Clinics. 2012;59(5):1147-1165. 22. van Donge T, Samiee‐Zafarghandy S, Pfister M, et al. Methadone dosing strategies in preterm neonates can be simplified. British journal of clinical pharmacology. 2019;85(6):1348-1356. 23. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatric nephrology. 2011;26(10):1843- 1849. 24. Vieux R, Hascoet J-M, Merdariu D, Fresson J, Guillemin F. Glomerular filtration rate reference values in very preterm infants. Pediatrics. 2010;125(5):e1186-e1192. 25. van Donge T, Allegaert K, Gotta V, et al. Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life. Pediatric Nephrology. 2020:1-11. 26. Van Donge T, Allegaert K, Pfister M, Smits A, Den Anker V, Nicolaas J. Creatinine trends to detect ibuprofen-related maturational adverse drug events in neonatal life: a simulation study for the ELBW newborn Creatinine trends during ibuprofen exposure in ELBW newborns. Frontiers in Pharmacology. 2020;11:2387. 27. Ceriotti F. Establishing pediatric reference intervals: a challenging task. In: Oxford University Press; 2012. 28. Colantonio DA, Kyriakopoulou L, Chan MK, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clinical chemistry. 2012;58(5):854-868. 29. Shaw JL, Binesh Marvasti T, Colantonio D, Adeli K. Pediatric reference intervals: challenges and recent initiatives. Critical reviews in clinical laboratory sciences. 2013;50(2):37-50. 30. Neely M, Bayard D, Desai A, Kovanda L, Edginton A. Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology. The Journal of Clinical Pharmacology. 2018;58:S73-S85. 31. Balevic SJ, Cohen‐Wolkowiez M. Innovative study designs optimizing clinical pharmacology research in infants and children. The Journal of Clinical Pharmacology. 2018;58:S58-S72. 32. Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. The American journal of drug and alcohol abuse. 1981;8(2):203-213. 33. Finnegan LP, Connaughton Jr JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addictive diseases. 1975;2(1-2):141-158. 34. Hudak M, Tan R. Committee on drugs; Committee on fetus and newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-560. 35. Eerdekens M, Beuter C, Lefeber C, van den Anker J. The challenge of developing pain medications for children: therapeutic needs and future perspectives. Journal of pain research. 2019;12:1649. 36. Zhao W, Leroux S, Jacqz-Aigrain E. Dosage individualization in children: integration of pharmacometrics in clinical practice. World journal of pediatrics. 2014;10(3):197-203. 37. Mehrotra N, Bhattaram A, Earp JC, et al. Role of quantitative clinical pharmacology in pediatric approval and labeling. Drug Metabolism and Disposition. 2016;44(7):924-933. 38. Bonate PL. Be a Model Communicator: And Sell Your Models to Anyone. Peter Bonate; 2014.